{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:10:59Z","timestamp":1790622659578,"version":"4.1.0"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["179842"],"award-info":[{"award-number":["179842"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>Cholera outbreaks have been rapidly increasing around the world. While long-term cholera prevention and control measures rely on improvements in water, sanitation, and hygiene, oral cholera vaccines (OCVs) are used for prevention and control in the short-to-medium term. OCVs lack the market incentives available in other more profitable disease areas. The development of OCVs was made possible through an alternative innovation model, which sustained innovation across multiple generations of the product for more than three decades. To examine how this alternative innovation model worked, we conducted 18 semi-structured interviews with key stakeholders related to the development of several OCVs, including \u201cDukoral\u201d, \u201cShanchol\u201d, and \u201cEuvichol-Plus\u201d, as well as additional cholera vaccines currently under development. Interview data was analyzed thematically according to the resources used by organizations (including funding, knowledge, relationships, and manufacturing), and the practices they implemented during each stage of the R&amp;D process (including knowledge management and intellectual property strategies, approaches to transparency, and global access strategies). Next, we created participatory network maps to illustrate the structure of the relationships between stakeholders and how these evolved over time. We found that a core group of stakeholders were able to influence policies to promote the use of OCVs, and successfully develop, finance, and obtain WHO Prequalification for safe, effective, and affordable OCVs for global procurement and distribution. The evolution of OCVs demonstrates how a collaborative network innovation model can successfully develop new pharmaceutical products that are affordable and well-suited for use in context. This model could be applied to other areas of pharmaceutical innovation, such as pandemic preparedness, for more equitable outcomes for global public health.<\/jats:p>","DOI":"10.1371\/journal.pgph.0003599","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T19:57:29Z","timestamp":1737143849000},"page":"e0003599","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["The 30-year evolution of oral cholera vaccines: A case study of a collaborative network alternative innovation model"],"prefix":"10.1371","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6555-6806","authenticated-orcid":true,"given":"Kaitlin","family":"Large","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8670-0096","authenticated-orcid":true,"given":"Adrian Alonso","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia","family":"Slovenski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suerie","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"pgph.0003599.ref001","unstructured":"WHO. Cholera. 11 Dec 2023 [cited 2024 Feb 1]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cholera"},{"key":"pgph.0003599.ref002","volume-title":"Cholera cases soar globally amid shortage of vaccines","author":"W Strzy\u017cy\u0144ska","year":"2024"},{"key":"pgph.0003599.ref003","unstructured":"WHO. Cholera vaccines: WHO position paper \u2013 August 2017. 2017 [cited 2024 Feb 1]. Available from: https:\/\/www.who.int\/publications-detail-redirect\/who-wer9234-477-500"},{"issue":"6","key":"pgph.0003599.ref004","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1524-4733.2009.00562.x","article-title":"Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis","volume":"12","author":"DOMI Cholera Economics Study Group","year":"2009","journal-title":"Value Health"},{"key":"pgph.0003599.ref005","volume-title":"Sources of infection & Risk factors | Cholera","author":"CDC","year":"2022"},{"key":"pgph.0003599.ref006","first-page":"175","article-title":"Drug discovery and development for neglected diseases: the DNDi model","volume":"5","author":"E Chatelain","year":"2011","journal-title":"Drug Des Devel Ther"},{"key":"pgph.0003599.ref007","author":"UNC Gillings School of Global Public Health","year":"2023"},{"key":"pgph.0003599.ref008","unstructured":"GTFCC. Section 2: Outbreak confirmation | Cholera outbreak response field manual. 2020 [cited 2024 Feb 1]. Available from: https:\/\/choleraoutbreak.org\/book-page\/section-2-outbreak-confirmation"},{"key":"pgph.0003599.ref009","unstructured":"WIPO. Technology transfer and voluntary licensing to address the global cholera vaccine shortage and Africa\u2019s vaccine production goals. 27 Apr 2023 [cited 2024 Feb 1]. Available from: https:\/\/www.wipo.int\/policy\/en\/news\/global_health\/2023\/news_0006.html"},{"issue":"Suppl 1","key":"pgph.0003599.ref010","doi-asserted-by":"crossref","first-page":"A118","DOI":"10.1016\/j.vaccine.2019.12.011","article-title":"Current and future cholera vaccines","volume":"38","author":"H Shaikh","year":"2020","journal-title":"Vaccine"},{"key":"pgph.0003599.ref011","volume-title":"Vaccines, Prevention and control | Cholera","author":"CDC","year":"2023"},{"key":"pgph.0003599.ref012","unstructured":"Partners In Health. Why the global cholera vaccine shortage goes unnoticed despite high demand. 29 Nov 2022 [cited 2024 Feb 1]. Available from: https:\/\/www.pih.org\/article\/why-global-cholera-vaccine-shortage-goes-unnoticed-despite-high-demand"},{"key":"pgph.0003599.ref013","unstructured":"Anderson S. Cholera vaccine shortage to continue through 2025. 23 May 2023 [cited 2024 Feb 1]. Available from: https:\/\/healthpolicy-watch.news\/cholera-vaccine-shortage-to-continue-through-2025\/."},{"key":"pgph.0003599.ref014","unstructured":"Hackett DW. Cholera vaccine shortage perpetuates outbreak risk in 2023. 7 Dec 2023 [cited 2024 Feb 6]. Available from: https:\/\/www.precisionvaccinations.com\/2023\/12\/07\/cholera-vaccine-shortage-perpetuates-outbreak-risk-2023"},{"key":"pgph.0003599.ref015","unstructured":"WHO. Shortage of cholera vaccines leads to temporary suspension of two-dose strategy, as cases rise worldwide. 19 Oct 2022 [cited 2024 Feb 1]. Available from: https:\/\/www.who.int\/news\/item\/19-10-2022-shortage-of-cholera-vaccines-leads-to-temporary-suspension-of-two-dose-strategy--as-cases-rise-worldwide"},{"key":"pgph.0003599.ref016","unstructured":"WHO. WHO prequalifies new oral simplified vaccine for cholera. 18 Apr 2024 [cited 2024 Jul 21]. Available from: https:\/\/www.who.int\/news\/item\/18-04-2024-who-prequalifies-new-oral-simplified-vaccine-for-cholera"},{"issue":"12","key":"pgph.0003599.ref017","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nchembio837","article-title":"Drug discovery and development for neglected parasitic diseases","volume":"2","author":"AR Renslo","year":"2006","journal-title":"Nat Chem Biol"},{"issue":"9324","key":"pgph.0003599.ref018","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/S0140-6736(02)09096-7","article-title":"Drug development for neglected diseases: a deficient market and a public-health policy failure","volume":"359","author":"P Trouiller","year":"2002","journal-title":"Lancet"},{"key":"pgph.0003599.ref019","doi-asserted-by":"crossref","DOI":"10.1353\/book.59674","volume-title":"Pandemics, pills, and politics: governing global health security","author":"S Elbe","year":"2018"},{"issue":"4","key":"pgph.0003599.ref020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1021\/acsinfecdis.1c00527","article-title":"The pandemic response box\u2500accelerating drug discovery efforts after disease outbreaks","volume":"8","author":"K Samby","year":"2022","journal-title":"ACS Infect Dis"},{"key":"pgph.0003599.ref021","volume-title":"Knowledge Portal on Innovation and Access to Medicines","author":"Knowledge Portal on Innovation and Access to Medicines","year":"n.d"},{"key":"pgph.0003599.ref022","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1471-2288-13-117","article-title":"Using the framework method for the analysis of qualitative data in multi-disciplinary health research","volume":"13","author":"NK Gale","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"pgph.0003599.ref023","volume-title":"Thematic Analysis","author":"V Braun","year":"2021"},{"key":"pgph.0003599.ref024","unstructured":"valneva. DUKORAL, Cholera vaccine. n.d. [cited 2024 Feb 1]. Available from: https:\/\/www.valneva.co.uk\/healthcare-professionals\/dukoral"},{"issue":"12","key":"pgph.0003599.ref025","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.3390\/vaccines9121482","article-title":"Oral cholera vaccine efficacy and effectiveness","volume":"9","author":"KR Song","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"46","key":"pgph.0003599.ref026","doi-asserted-by":"crossref","first-page":"6360","DOI":"10.1016\/j.vaccine.2015.08.075","article-title":"A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines","volume":"33","author":"YO Baik","year":"2015","journal-title":"Vaccine"},{"key":"pgph.0003599.ref027","volume-title":"Euvichol-S, simplified formulation of oral cholera vaccine, licensed by Korean regulatory agency","author":"EurekAlert!","year":"2023"},{"key":"pgph.0003599.ref028","volume-title":"IVI begins clinical development of DuoChol oral cholera vaccine","author":"IVI","year":"2023"},{"issue":"12 Suppl 2","key":"pgph.0003599.ref029","doi-asserted-by":"crossref","first-page":"S742","DOI":"10.1093\/infdis\/jiab423","article-title":"Modern history of cholera vaccines and the pivotal role of icddr,b","volume":"224","author":"J Holmgren","year":"2021","journal-title":"J Infect Dis"},{"issue":"8932","key":"pgph.0003599.ref030","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(94)90755-2","article-title":"Protective efficacy of oral whole-cell\/recombinant-B-subunit cholera vaccine in Peruvian military recruits","volume":"344","author":"JL Sanchez","year":"1994","journal-title":"Lancet"},{"key":"pgph.0003599.ref031","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1016\/j.vaccine.2018.09.026","article-title":"The Euvichol story \u2013 Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships","volume":"36","author":"L Odevall","year":"2018","journal-title":"Vaccine"},{"issue":"10","key":"pgph.0003599.ref032","first-page":"837","article-title":"Mass vaccination with a two-dose oral cholera vaccine in a refugee camp","volume":"77","author":"D Legros","year":"1999","journal-title":"Bull World Health Organ"},{"issue":"9","key":"pgph.0003599.ref033","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3201\/eid0909.020443","article-title":"Reemergence of epidemic Vibrio cholerae O139, Bangladesh","volume":"9","author":"SM Faruque","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"pgph.0003599.ref034","unstructured":"IVI. History. IVI [Internet]. n.d. [cited 2024 Feb 1]. Available from: https:\/\/www.ivi.int\/who-we-are\/history\/."},{"key":"pgph.0003599.ref035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1471-2458-9-99","article-title":"Oral cholera vaccine use in Zanzibar: socioeconomic and behavioural features affecting demand and acceptance","volume":"9","author":"C Schaetti","year":"2009","journal-title":"BMC Public Health"},{"issue":"8","key":"pgph.0003599.ref036","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJMoa043323","article-title":"Effectiveness of mass oral cholera vaccination in Beira, Mozambique","volume":"352","author":"MES Lucas","year":"2005","journal-title":"N Engl J Med"},{"key":"pgph.0003599.ref037","volume-title":"International vaccine institute receives $40 million grant from the Bill & Melinda Gates Foundation","author":"BMGF","year":"2000"},{"issue":"11","key":"pgph.0003599.ref038","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1473-3099(12)70196-2","article-title":"Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study","volume":"12","author":"AM Khatib","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"pgph.0003599.ref039","first-page":"171","article-title":"Truth and direct-to-consumer advertising in Canada of DUKORAL for traveler\u2019s diarrhea prevention","volume":"65","author":"R Zimmer","year":"2019","journal-title":"Can Fam Physician"},{"key":"pgph.0003599.ref040","unstructured":"WHO. Regulatory agencies | WHO - prequalification of medical products (IVDs, medicines, vaccines and immunization devices, vector control). n.d. [cited 2024 Feb 1]. Available from: https:\/\/extranet.who.int\/prequal\/vaccines\/regulatory-agencies"},{"issue":"12","key":"pgph.0003599.ref041","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S1473-3099(13)70273-1","article-title":"5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial","volume":"13","author":"SK Bhattacharya","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"pgph.0003599.ref042","author":"CDC","year":"2023"},{"key":"pgph.0003599.ref043","unstructured":"GTFCC. Global task force on cholera control. n.d. [cited 2024 Feb 1]. Available from: https:\/\/www.gtfcc.org\/."},{"key":"pgph.0003599.ref044","unstructured":"WHO. Cholera vaccine stockpiles. n.d. [cited 2024 Feb 1]. Available from: https:\/\/www.who.int\/groups\/icg\/cholera\/stockpiles"},{"issue":"9773","key":"pgph.0003599.ref045","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0140-6736(11)60273-0","article-title":"Transmission dynamics and control of cholera in Haiti: an epidemic model","volume":"377","author":"JR Andrews","year":"2011","journal-title":"Lancet"},{"issue":"22","key":"pgph.0003599.ref046","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa1312680","article-title":"Use of Vibrio cholerae vaccine in an outbreak in Guinea","volume":"370","author":"FJ Luquero","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"pgph.0003599.ref047","doi-asserted-by":"crossref","first-page":"e1001901","DOI":"10.1371\/journal.pmed.1001901","article-title":"The first use of the global oral cholera vaccine emergency stockpile: lessons from South Sudan","volume":"12","author":"A Abubakar","year":"2015","journal-title":"PLoS Med"},{"key":"pgph.0003599.ref048","volume-title":"\uc720\ubc14\uc774\uc624\ub85c\uc9c1\uc2a4","author":"EuBiologics","year":"n.d"},{"key":"pgph.0003599.ref049","volume-title":"Euvichol-S, simplified formulation of oral cholera vaccine, licensed by Korean regulatory agency","author":"IVI","year":"2023"},{"key":"pgph.0003599.ref050","volume-title":"Preclinical toxicology testing and IND application for a novel cholera conjugate vaccine","author":"GTFCC","year":"2021"},{"key":"pgph.0003599.ref051","volume-title":"International Vaccine Institute \u2013 Cholera vaccine clinical trial","author":"Open Philanthropy","year":"2022"},{"key":"pgph.0003599.ref052","author":"RIGHT Foundation","year":"n.d"},{"key":"pgph.0003599.ref053","volume-title":"IVI welcomes Bangladesh\u2019s accession to IVI","author":"IVI","year":"2021"},{"key":"pgph.0003599.ref054","author":"DNDi","year":"2021"},{"key":"pgph.0003599.ref055","volume-title":"Home - READDI Making antiviral medicines to prevent another global crisis","author":"READDI","year":"n.d"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0003599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T19:57:48Z","timestamp":1737143868000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0003599"}},"subtitle":[],"editor":[{"given":"Syed Shahid","family":"Abbas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0003599","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]}}}